"Variations in two genes involved in gut hormone pathways may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines."
"The GLP1 receptor variant rs10305420 was associated with slightly more weight loss in those carrying this variant compared with those who lacked it."
"Another variant, rs1800437, was associated with nausea and vomiting in people taking tirzepatide but was not associated with how much weight they lost."
"Non-genetic factors such as sex, drug type, dose and duration appear to explain a substantially larger proportion of variability."
Genetic variations in two genes related to gut hormone pathways may influence the effectiveness and side effects of GLP1 medications for weight loss. A study involving 27,885 patients found that the rs10305420 variant was linked to greater weight loss, while rs1800437 was associated with nausea from tirzepatide. Despite these findings, the overall genetic impact on weight loss was modest, with non-genetic factors such as sex and drug type playing a more significant role in treatment outcomes for obesity.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]